The role of healthcare providers in the roll out of preexposure prophylaxis

Current Opinion in HIV and AIDS

Volumn 11, Issue 1, 2016, Pages 41-48

  Krakower, Douglas S ^a,b,c   Mayer, Kenneth H ^a,b,c  

^a FENWAY INSTITUTE   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

healthcare providers; HIV; implementation; preexposure prophylaxis; risk assessment

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

AWARENESS; DRUG EFFICACY; DRUG SAFETY; HEALTH CARE PERSONNEL; HEALTH CARE UTILIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MASS COMMUNICATION; PATIENT IDENTIFICATION; PRE-EXPOSURE PROPHYLAXIS; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; UNITED STATES; CHEMOPROPHYLAXIS; DISEASE TRANSMISSION; HIV INFECTIONS; ORGANIZATION AND MANAGEMENT; PATIENT ATTITUDE; PREVENTION AND CONTROL; PROCEDURES; TRANSMISSION;

CHEMOPREVENTION; DISEASE TRANSMISSION, INFECTIOUS; HEALTH PERSONNEL; HIV INFECTIONS; HUMANS; PATIENT ACCEPTANCE OF HEALTH CARE; PRE-EXPOSURE PROPHYLAXIS;

EID: 84951906300     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0000000000000206     Document Type: Review

References (47)

1. Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med 2012; 367:399-410.
2. Choopanya K, Martin M, Suntharasamai P, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2013; 381:2083-2090.
3. Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010; 363:2587-2599.
4. Marrazzo JM, Ramjee G, Richardson BA, et al. Tenofovir-based preexposure prophylaxis for HIV infection among African women. N Engl J Med 2015; 372:509-518.
5. Thigpen MC, Kebaabetswe PM, Paxton LA, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med 2012; 367:423-434.
6. Van Damme L, Corneli A, Ahmed K, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med 2012; 367:411-422.
7. FDA. Advisory committee supports approval of Gilead's Truvada1 for reducing the risk of acquiring HIV. The New York Times; 11 May 2012.
8. US Public Health Service. Preexposure prophylaxis for the prevention of HIV infection in the United States-2014: a clinical practice guideline. http://www.cdc. gov/hiv/pdf/PrEPguidelines2014. pdf. [Accessed 6 August 2015]
9. Cohen SE, Vittinghoff E, Bacon O, et al. High interest in preexposure prophylaxis among men who have sex with men at risk for HIV infection: baseline data from the US PrEP demonstration project. J Acquir Immune Defic Syndr 2015; 68:439-448.
10. Baeten J, Heffron R, Kidoguchi L, et al. Near elimination of HIV transmission in a demonstration project of PrEP and ART [abstract 24]. Conference on retroviruses and opportunistic infections. Seattle, Washington: ; 2015; 23-26 February.
11. Hoagland B, Veloso VG, De Boni RB, et al. Preexposure prophylaxis (PrEP) uptake and associated factors among MSM and TGW in the PrEP Brasil demonstration project [abstract TUACO205LB]. 8th International AIDS Society Conference on HIV pathogenesis, treatment, and prevention. Vancouver, British Columbia: ; 2015; 19-22 July.
12. Flash C, Landovitz R, Mera Giler R, et al. Two years of Truvada for preexposure prophylaxis utilization in the US. J Int AIDS Soc 2014; 17:19730.
13. PrEPWatch. http://www.prepwatch. org/prep-Access/guidance/. [Accessed 1 August 2015]
14. Krakower DS, Oldenburg CE, Mitty JA, et al. Knowledge, beliefs and practices regarding antiretroviral medications for HIV prevention: results from a survey of healthcare providers in New England. PLoS One 2015; 10:e0132398.
15. Petroll A, Bogart LM, Horvath KJ, Mcauliffe T. PrEP knowledge, attitudes, awareness, and experience among a national sample of US primary care and HIV providers [abstract 41]. 10th International Conference on HIV treatment and prevention adherence. Miami, Florida: ; 2015; 28-30 June.
16. Karris MY, Beekmann SE, Mehta SR, et al. Are we prepped for preexposure prophylaxis (PrEP)? Provider opinions on the real-world use of PrEP in the United States and Canada. Clin Infect Dis 2014; 58:704-712.
17. Krakower D, Ware N, Mitty JA, et al. HIV providers' perceived barriers and facilitators to implementing preexposure prophylaxis in care settings: a qualitative study. AIDS Behav 2014; 18:1712-1721.
18. Krakower DS, Beekmann SE, Polgreen PM, Mayer KH. Frontline practices with HIV prevention: a survey of US infectious disease physicians. Conference on retroviruses and opportunistic infections [abstract 1083]. Seattle, Washington: ; 2015; 23-26 February.
19. Calabrese SK, Earnshaw VA, Underhill K, et al. The impact of patient race on clinical decisions related to prescribing HIV preexposure prophylaxis (PrEP): assumptions about sexual risk compensation and implications for access. AIDS Behav 2014; 18:226-240.
20. Henderson F, Taylor A, Chirwa L, et al. Characteristics and oral PrEP adherence in the TDF2 open-label extension in Botswana [abstract TUACO203]. 8th International AIDS Society Conference on HIV pathogenesis, treatment, and prevention. Vancouver, British Columbia: ; 2015; 19-22 July.
21. AIDS Vaccine Advocacy Coalition. Ongoing and planned PrEP evaluation studies. http://www.avac. org/resource/ongoing-And-planned-prep-evaluation-studies. [Accessed 1 August 2015]
22. McCormack S, Dunn D. Pragmatic open-label randomised trial of preexposure prophylaxis: the PROUD study [abstract 22LB]. Conference on retroviruses and opportunistic infections. Seattle, Washington: ; 2015; 23-26 February.
23. Molina JM, Capitant C, Charreau I, et al. On demand PrEP with oral TDF-FTC in MSM: results of the ANRS Ipergay Trial [abstract 23LB]. Conference on retroviruses and opportunistic infections 2015. Seattle, Washington: ; 2015; 23-26 February.
24. Tang EC, Sobieszczyk ME, Shu E, et al. Provider attitudes toward oral preexposure prophylaxis for HIV prevention among high-risk men who have sex with men in Lima, Peru. AIDS Res Hum Retroviruses 2014; 30:416-424.
25. Sharma M, Wilton J, Senn H, et al. Preparing for PrEP: perceptions and readiness of Canadian physicians for the implementation of HIV preexposure prophylaxis. PLoS One 2014; 9:e105283.
26. Lippman SA, Koester KA, Amico KR, et al. Client and provider perspectives on new HIV prevention tools for MSM in the Americas. PLoS One 2015; 10:e0121044.
27. Venter F, Allais L, Richter M. Exposure ethics: does HIV preexposure prophylaxis raise ethical problems for the healthcare provider and policy maker? Bioethics 2014; 28:269-274.
28. Desai M, Gafos M, Dolling D, et al. Healthcare providers' knowledge of, attitudes to and practice of preexposure prophylaxis for HIV infection. HIV Med 2015.
29. Lanier Y, Castellanos T, Barrow RY, et al. Brief sexual histories and routine HIV/STD testing by medical providers. AIDS Patient Care STDS 2014; 28:113-120.
30. Sherman MD, Kauth MR, Shipherd JC, Street RL Jr. Communication between VA providers and sexual and gender minority veterans: a pilot study. Psychol Serv 2014; 11:235-242.
31. Stott DB. The training needs of general practitioners in the exploration of sexual health matters and providing sexual healthcare to lesbian, gay and bisexual patients. Med Teach 2013; 35:752-759.
32. Krakower DS, Oldenburg CE, Mimiaga MJ, et al. Patient-provider communication about sexual behaviors and preexposure prophylaxis: results from a national online survey of men who have sex with men in the United States [abstract TUPEC506]. 8th International AIDS Society Conference on HIV pathogenesis, treatment, and prevention. Vancouver, British Columbia: ; 2015; 19-22 July.
33. Smith DK, Pals SL, Herbst JH, et al. Development of a clinical screening index predictive of incident HIV infection among men who have sex with men in the United States. J Acquir Immune Defic Syndr 2012; 60:421-427.
34. Smith DK, Pan Y, Rose CE, et al. A brief screening tool to assess the risk of contracting HIV infection among active injection drug users. J Addict Med 2015; 9:226-232.
35. Jones J, Stephenson R, Smith DK, et al. Acceptability and willingness among men who have sex with men (MSM) to use a tablet-based HIV risk assessment in a clinical setting. Springerplus 2014; 3:708.
36. Langhaug LF, Cheung YB, Pascoe SJ, et al. How you ask really matters: randomised comparison of four sexual behaviour questionnaire delivery modes in Zimbabwean youth. Sex Transm Infect 2011; 87:165-173.
37. Jensen RE, Rothrock NE, DeWitt EM, et al. The role of technical advances in the adoption and integration of patient-reported outcomes in clinical care. Med Care 2015; 53:153-159.
38. Vogel J, Brown JS, Land T, et al. MDPHnet: secure, distributed sharing of electronic health record data for public health surveillance, evaluation, and planning. Am J Public Health 2014; 104:2265-2270.
39. Rogers EM. Diffusion of innovations. 5th ed New York: Free Press; 2003.
40. Berwick DM. Disseminating innovations in healthcare. JAMA 2003; 289:1969-1975.
41. Liu A, Cohen S, Follansbee S, et al. Early experiences implementing preexposure prophylaxis (PrEP) for HIV prevention in San Francisco. PLoS Med 2014; 11:e1001613.
42. Mayer K, Krakower D, Levine K, et al. Significant increases in HIV preexposure prophylaxis (PrEP) uptake in Boston, a Boston Community Health Center in 2014: who are the recent users? [abstract TUPEC508]. 8th International AIDS Society Conference on HIV pathogenesis, treatment, and prevention. Vancouver, British Columbia: ; 2015; 19-22 July.
43. New York State Department of Health. Pre exposure prophylaxis (PrEP) and non-occupational post-exposure prophylaxis (PEP). https://www.health. ny. gov/diseases/aids/general/prep/index. htm. [Accessed 6 August 2015]
44. Blumenthal J, Jain S, Krakower D, et al. Knowledge is power! Increased provider knowledge scores regarding preexposure prophylaxis (PrEP) are associated with higher rates of PrEP prescription and future intent to prescribe PrEP. AIDS Behav 2015; 19:802-810.
45. Golub SA. PrEP can 'Do More': synergistic effects on primary care, insurance and mental health [abstract 174]. 10th International Conference on HIV treatment and prevention adherence. Miami, Florida: ; 2015; 28-30 June.
46. INSIGHT START Study Group. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med 2015; 373:795-807.
47. TEMPRANO ANRS 12136 Study Group. A trial of early antiretrovirals and isoniazid preventive therapy in Africa. N Engl J Med 2015; 373:808-822.